David P. Bonita - Jun 16, 2023 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Signature
/s/ Laurent Chardonnet, Attorney-in-Fact
Stock symbol
PRLD
Transactions as of
Jun 16, 2023
Transactions value $
$0
Form type
4
Date filed
6/21/2023, 04:12 PM
Previous filing
Jun 15, 2023
Next filing
Sep 21, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRLD Director Stock Option (Right to Buy) Award $0 +23.5K $0.00 23.5K Jun 16, 2023 Common Stock 23.5K $5.56 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2 Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP.